Burrill & Co. swells its life sciences fund to $505M

Amidst a tepid venture capital environment in the world of biotechnology, one VC firm has restocked its war chest to the tune of $505 million. San Francisco's Burrill & Co. closed its latest fund and looks to invest in healthcare and life sciences firms, including makers of devices, diagnostics and therapeutics. Report